We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Q3 earnings cycle is winding down at this point, with several companies delivering strong results and seeing favorable post-earnings reactions as a result.
Notable winners in this earnings cycle include Hasbro (HAS - Free Report) , IDEXX Laboratories (IDXX - Free Report) , and TG Therapeutics (TGTX - Free Report) , all of which also raised their guidance. The trio has also shown relative strength against the broader market over the past month, outperforming amid the recent volatility spike.
Image Source: Zacks Investment Research
Hasbro Reports Strong Segment Strength
Hasbro, a current Zacks Rank #1 (Strong Buy), designs, manufactures, and markets games, toys, and licensed products, offering traditional, high-tech, and digital play experiences. Its latest results showed nice positivity, with revenue climbing 15% YoY to roughly $1.6 billion and adjusted earnings soaring 70% to $2.90 per share, comfortably exceeding expectations.
Image Source: Zacks Investment Research
The Wizards of the Coast and Digital Gaming segment led the strong performance, with revenue jumping 31% YoY. Magic: The Gathering remained the biggest highlight, with quarterly sales surpassing $600 million for the first time and up 34% YoY.
Image Source: Zacks Investment Research
Given the strong results, management raised its FY26 revenue growth outlook and doubled its share repurchase target for the year, further boosting sentiment. Shares also reflect a solid opportunity from an income-focused standpoint, currently yielding a solid 2.3% annually.
Growth Outlook Remains Strong for IDXX
IDEXX Laboratories, a current Zacks Rank #2 (Buy), provides diagnostic testing products, software, and other solutions primarily focused on veterinary healthcare. Shares surged after its Q3 release, with EPS of $4.01 up 18% YoY and revenue up 10% to $1.2 billion.
Image Source: Zacks Investment Research
Companion Animal Group Diagnostics recurring revenue was a big highlight, climbing 11% YoY thanks to higher testing volumes and continued adoption of its diagnostic offerings. The overall solid results led management to raise its FY26 revenue guidance into a range of $4.74 – $4.77 billion, with EPS now expected between $14.96 – $15.16 per share.
Earnings estimates have moved higher nearly across the board following the updated outlook, with earnings on track to grow by double digits in its current and next fiscal years.
Image Source: Zacks Investment Research
TGTX Shares Hover at All-Time Highs
TG Therapeutics is a commercial-stage biotechnology company focused on treatments for B-cell diseases. Like those above, TGTX delivered strong Q3 results, with revenue jumping 61% YoY to $260 million, with EPS of $0.35 exceeding the $0.28 Zacks Consensus estimate.
The company’s EPS outlook remains highly bullish, with estimates rising across all timeframes.
Image Source: Zacks Investment Research
BRIUMVI, its treatment for relapsing forms of multiple sclerosis, continues to reflect the primary growth driver, with U.S. net product sales climbing 52% YoY to $232.6 million thanks to increasing physician adoption and a growing patient base.
Given the strength, management raised its FY26 global revenue guidance to approximately $1 billion from $950 million previously. Its outlook for U.S. BRIUMVI sales was also raised into a range of $915 – $920 million.
Image Source: Zacks Investment Research
Bottom Line
The Q3 earnings season has delivered several big winners, with Hasbro (HAS - Free Report) , IDEXX Laboratories (IDXX - Free Report) , and TG Therapeutics (TGTX - Free Report) all posting strong results that have helped drive relative strength over the last month, with each raising guidance in one way or another.
Image: Bigstock
3 Stocks Rallying After Strong Q3 Earnings and Raised Guidance
Key Takeaways
The Q3 earnings cycle is winding down at this point, with several companies delivering strong results and seeing favorable post-earnings reactions as a result.
Notable winners in this earnings cycle include Hasbro (HAS - Free Report) , IDEXX Laboratories (IDXX - Free Report) , and TG Therapeutics (TGTX - Free Report) , all of which also raised their guidance. The trio has also shown relative strength against the broader market over the past month, outperforming amid the recent volatility spike.
Image Source: Zacks Investment Research
Hasbro Reports Strong Segment Strength
Hasbro, a current Zacks Rank #1 (Strong Buy), designs, manufactures, and markets games, toys, and licensed products, offering traditional, high-tech, and digital play experiences. Its latest results showed nice positivity, with revenue climbing 15% YoY to roughly $1.6 billion and adjusted earnings soaring 70% to $2.90 per share, comfortably exceeding expectations.
Image Source: Zacks Investment Research
The Wizards of the Coast and Digital Gaming segment led the strong performance, with revenue jumping 31% YoY. Magic: The Gathering remained the biggest highlight, with quarterly sales surpassing $600 million for the first time and up 34% YoY.
Image Source: Zacks Investment Research
Given the strong results, management raised its FY26 revenue growth outlook and doubled its share repurchase target for the year, further boosting sentiment. Shares also reflect a solid opportunity from an income-focused standpoint, currently yielding a solid 2.3% annually.
Growth Outlook Remains Strong for IDXX
IDEXX Laboratories, a current Zacks Rank #2 (Buy), provides diagnostic testing products, software, and other solutions primarily focused on veterinary healthcare. Shares surged after its Q3 release, with EPS of $4.01 up 18% YoY and revenue up 10% to $1.2 billion.
Image Source: Zacks Investment Research
Companion Animal Group Diagnostics recurring revenue was a big highlight, climbing 11% YoY thanks to higher testing volumes and continued adoption of its diagnostic offerings. The overall solid results led management to raise its FY26 revenue guidance into a range of $4.74 – $4.77 billion, with EPS now expected between $14.96 – $15.16 per share.
Earnings estimates have moved higher nearly across the board following the updated outlook, with earnings on track to grow by double digits in its current and next fiscal years.
Image Source: Zacks Investment Research
TGTX Shares Hover at All-Time Highs
TG Therapeutics is a commercial-stage biotechnology company focused on treatments for B-cell diseases. Like those above, TGTX delivered strong Q3 results, with revenue jumping 61% YoY to $260 million, with EPS of $0.35 exceeding the $0.28 Zacks Consensus estimate.
The company’s EPS outlook remains highly bullish, with estimates rising across all timeframes.
Image Source: Zacks Investment Research
BRIUMVI, its treatment for relapsing forms of multiple sclerosis, continues to reflect the primary growth driver, with U.S. net product sales climbing 52% YoY to $232.6 million thanks to increasing physician adoption and a growing patient base.
Given the strength, management raised its FY26 global revenue guidance to approximately $1 billion from $950 million previously. Its outlook for U.S. BRIUMVI sales was also raised into a range of $915 – $920 million.
Image Source: Zacks Investment Research
Bottom Line
The Q3 earnings season has delivered several big winners, with Hasbro (HAS - Free Report) , IDEXX Laboratories (IDXX - Free Report) , and TG Therapeutics (TGTX - Free Report) all posting strong results that have helped drive relative strength over the last month, with each raising guidance in one way or another.